Abstract The SARS-CoV-2 pandemic, now in its third year, has had a profound impact on
public health and economics all over the world. Different populations showed varied …

Abstract There have been 774,075,242 cases of COVID-19 and 7,012,986 deaths worldwide
as of January 2024. In the early stages of the pandemic, there was an urgent need to reduce …

Inflammatory bowel disease (IBD)—consisting of ulcerative colitis and Crohn's disease—is a
complex, heterogeneous, immune-mediated inflammatory condition with a multifactorial …

Background The selective serotonin reuptake inhibitors (SSRIs) fluoxetine and fluvoxamine
were repurposed for the treatment of early COVID-19 based on their antiviral activity in vitro …

We have read with great interest the study by de Kirenga et al., about efficacy and safety of
fluvoxamine with mortality and symptom resolution among inpatients with COVID-19 [1] …

Infectious diseases are emerging and re-emerging far more frequently than many
appreciate. In the past two decades alone, there have been numerous outbreaks (eg, Ebola …

Background While existing studies have suggested an increased risk of COVID-19 in
patients with depression, the causal impact of MDD on the severity of COVID-19 remains to …

The pandemic caused by SARS-CoV-2 is still a major health problem. Newly emerging
variants and long-COVID-19 represent a challenge for the global health system. In …

Background Fluvoxamine is one of the selective serotonin reuptake inhibitors (SSRIs) that
are regarded as the first-line drugs to manage mental disorders. It has been also recognized …

Objectives This study assessed the clinical effectiveness of the combination of nirmatrelvir
and ritonavir (NMV-r) in treating nonhospitalized patients with COVID-19 who have …